BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 26723242)

  • 1. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
    Li BT; Ross DS; Aisner DL; Chaft JE; Hsu M; Kako SL; Kris MG; Varella-Garcia M; Arcila ME
    J Thorac Oncol; 2016 Mar; 11(3):414-9. PubMed ID: 26723242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
    Kim EK; Kim KA; Lee CY; Shim HS
    PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
    Eng J; Hsu M; Chaft JE; Kris MG; Arcila ME; Li BT
    Lung Cancer; 2016 Sep; 99():53-6. PubMed ID: 27565914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract.
    Rossi E; Villanacci V; Danesino C; Donato F; Nascimbeni R; Bassotti G
    Rev Esp Enferm Dig; 2011 Dec; 103(12):632-9. PubMed ID: 22217347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
    Li BT; Lee A; O'Toole S; Cooper W; Yu B; Chaft JE; Arcila ME; Kris MG; Pavlakis N
    Lung Cancer; 2015 Dec; 90(3):617-9. PubMed ID: 26559459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
    Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
    Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HER2 in the treatment of non-small cell lung cancer.
    Mar N; Vredenburgh JJ; Wasser JS
    Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
    Cancer; 2017 Nov; 123(21):4099-4105. PubMed ID: 28743157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
    J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
    Grob TJ; Kannengiesser I; Tsourlakis MC; Atanackovic D; Koenig AM; Vashist YK; Klose H; Marx AH; Koops S; Simon R; Izbicki JR; Bokemeyer C; Sauter G; Wilczak W
    Mod Pathol; 2012 Dec; 25(12):1566-73. PubMed ID: 22899293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
    Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C
    BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
    Ying JM; Liu XY; Guo L; Xie YQ; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population.
    Pala EE; Bayol U; Keskin EU; Ozguzer A; Kucuk U; Ozer O; Koc A
    Pathol Oncol Res; 2015 Sep; 21(4):1223-7. PubMed ID: 26060045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
    Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
    Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
    Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
    Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
    Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.